ERBB2 and breast cancer: Our results were comparable with breast cancer in general in which HR−/HER2+ achieved pCR significantly more often than the other subtypes and in which the prognostic impact of pCR was shown to be highest in HER2-positive (non-luminal) and triple-negative tumors [22].